Telesis Bio Inc. Overview
Pro stress-test →Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. The company manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.
Strategic Profile
Pro stress-test →Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow, with on-market solutions including BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, and BioXp Select kits. The company has growing collaborations with premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies.
Competitive Landscape
Pro stress-test →Primary competitors include Integrated DNA Technologies, Novus Biologicals, Azenta Life Sciences, Twist Bioscience, and DNA Script. Telesis Bio differentiates through integrated BioXp systems that automate entire workflows from DNA synthesis through NGS library preparation, positioning it as a workflow consolidation player rather than point-solution provider.
Industry Context
Telesis Bio Inc. operates in Synthetic biology instruments and automation.
Key facts
Founded: 2011 · Headquarters: San Diego, US · Employees: 125 · Revenue: $16.3M · Market cap: $1.78B